Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation
1. FDA granted Fast Track designation for GLSI-100 in breast cancer treatment. 2. Fast Track could expedite GLSI-100's approval process significantly. 3. 80% cancer recurrence reduction observed in Phase IIb study compared to standard therapies. 4. The Phase III trial FLAMINGO-01 is now underway, increasing GLSI's visibility. 5. CEO emphasizes potential significant impact on breast cancer patient outcomes.